Cardiovascular Mortality in Ovarian Cancer Patients: An Analysis of Patient Characteristics Using the SEER Database

Ismail Abdulrahman Al-Badawi1, Osama Alomar1, Saud Owaimer Alsehaimi1

  • 1Department of Obstetrics and Gynecology, King Faisal Specialist Hospital and Research Center, Riyadh 11564, Saudi Arabia.

PubMed

Insights

Cardiovascular disease (CVD) is a significant concern for ovarian cancer patients. Advanced stage, older age, and non-white race increase CVD risk, highlighting the need for targeted interventions to improve survival.

Area of Science:

  • Oncology
  • Cardiology
  • Epidemiology

Background:

  • Cardiovascular disease (CVD) significantly contributes to mortality in ovarian cancer patients.
  • Limited understanding exists regarding patient-specific risk factors for CVD in this population.

Purpose of the Study:

  • To identify patient characteristics associated with cardiovascular mortality in individuals diagnosed with ovarian cancer.
  • To inform targeted interventions for improving survival rates.

Main Methods:

  • Retrospective cohort study utilizing the SEER database (2000-2019).
  • Analysis of primary ovarian cancer cases.
  • Multivariable logistic regression to identify risk factors for cardiovascular death.

Main Results:

  • Poorly differentiated cancer and distant metastasis correlated with higher CVD mortality.
  • Age over 60, later diagnosis year, non-white race, bilateral disease, and distant stage were significant risk factors.
  • Patients aged 31-60 had lower CVD mortality risk compared to older patients.

Conclusions:

  • Cardiovascular mortality is a critical issue in ovarian cancer management.
  • Identifying high-risk patients (e.g., advanced stage, comorbidities) enables targeted cardiovascular health interventions.
  • Improving cardiovascular health in ovarian cancer patients may enhance overall survival.

Related Concept Videos

Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
383
Comparing the Survival Analysis of Two or More Groups01:20

Comparing the Survival Analysis of Two or More Groups

Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
222
Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
179